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Abstract
Background
To estimate the potential gain in life expectancy from addressing modifiable risk factors for
all-cause mortality (excluding suicide and deaths from accidents or violence) across specific
serious mental illness (SMI) subgroups, namely schizophrenia, schizoaffective disorders,
and bipolar disorders in a Western population.
Methods
We have used relative risks from recent meta-analyses to estimate the population attribution
fraction (PAF) due to specific modifiable risk factors known to be associated with all-cause
mortality within SMI. The potential gain in life expectancy at birth, age 50 and age 65 years
were assessed by estimating the combined effect of modifiable risk factors from different
contextual levels (behavioural, healthcare, social) and accounting for the effectiveness of
existing interventions tackling these factors. Projections for annual gain in life expectancy at
birth during a two-decade was estimated using the Annual Percentage Change (APC) for-
mula. The predicted estimates were based on mortality rates for year 2014–2015.
Results
Based on the effectiveness of existing interventions targeting these modifiable risk factors,
we estimated potential gain in life expectancy at birth of four (bipolar disorders), six (schi-
zoaffective disorders), or seven years (schizophrenia). The gain in life expectancy at age 50
years was three (bipolar disorders) or five (schizophrenia and schizoaffective disorders)
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years. The projected gain in life expectancy at age 65 years was three (bipolar disorders) or
four (schizophrenia and schizoaffective disorders) years.
Conclusions
The implementation of existing interventions targeting modifiable risk factors could narrow
the current mortality gap between the general and the SMI populations by 24% (men) to
28% (women). These projections represent ideal circumstances and without the limitation of
overestimation which often comes with PAFs.
Introduction
While life expectancy of the general population has increased steadily over the past century,
people with serious mental illness (SMI), including diagnoses of schizophrenia, schizoaffective
disorder, or bipolar disorder, have a reduced life expectancy of 13 years for men and 12 years
for women.[1] Around a fifth (20%) of the excess mortality in people with SMI is due to non-
natural deaths such as suicide and accidents but most deaths can be ascribed to common dis-
eases such as cardiovascular disease (CVD), respiratory illnesses, type 2 diabetes (T2DM), can-
cer, and digestive disorders.[2–4] These diseases, in their turn, are partly attributable to
modifiable unhealthy lifestyle factors (e.g. smoking, sedentarism, obesity, dyslipidemia),
adverse social context (e.g. social isolation, social deprivation), and suboptimal healthcare use
and efficiency (e.g. prevention, treatment adherence).[5–11] These modifiable risk factors
therefore provide opportunities for interventions to reduce the excess premature mortality
experienced by people with SMI.[7, 12, 13] Currently, there is limited evidence about the
potential gain in life expectancy among people with SMI by addressing multiple modifiable
risk factors for all-cause mortality. In this study we have quantified the potential gain in life
expectancy at birth and adult (ages 50 and 65) years that might realistically be achieved by eval-
uating the population attributional fraction due to specific modifiable risk factors and adjust-
ing these estimates by the published effectiveness of interventions from international studies
to address these factors. Projection of the expected annual increase in life expectancy at birth
over future decades can help monitor progress towards meeting set goals across specific SMI
groups. Therefore, this paper employed the life table method to estimate potentially attainable
gain in life expectancy over the life course for specific SMI subgroups and projected the gains
over a two-decade period.
Materials and methods
Data source
The existing literature was searched to estimate the prevalence of modifiable risk factors for
natural causes of all-cause mortality within the SMI population, the relative risk (RR) for all-
cause mortality attributed to those risk factors, and the effectiveness of health interventions
targeting modifiable risk factors within the SMI population. SMI was broadly defined to
include schizophrenia, schizoaffective disorders, and bipolar disorders. We searched PubMed
and reviews-focused electronic databases (e.g. Cochrane Database of Systematic Reviews,
DARE, DoPHER) to identify the most recent meta-analyses with relevant quantitative data
between 2008 and 2018. Where no meta-analyses were identified, data from the most recent
observational studies with representative populations were used. To facilitate comparison,
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priority was given to meta-analyses and observational studies with comparative data available
across all three SMI subgroups. Where schizophrenia and schizoaffective disorders were
grouped together or when only overall estimates were provided (rather than SMI subgroup
specific estimates), we have assumed the same estimate within each SMI subgroup. A descrip-
tion of the resources used to derive the study estimates is provided in S1 Table in S1 File.
Serious mental illness. There is inconsistent definition of SMI in practice, [14–16] how-
ever, the term commonly refers to people diagnosed with schizophrenia, schizoaffective disor-
ders, and bipolar disorder.[1, 2, 17] Major depressive disorders are also considered SMI, but
not consistently, and here we have decided to use a narrower definition and consider SMIs
with superior evidence about drivers of excess mortality.[18] While these disorders share some
common characteristics (i.e. overlap in clinical and genetic attributes), core risk factors and
associations, they also possess distinctive clinical features and healthcare burden.[19–24] For
instance, depression and panic disorders were suggested to be more severe within bipolar dis-
order, while lack of insight and early age onset were more common within schizophrenia.[20,
23] Since these distinctive clinical features may lead to differences in comorbidity rates, the
three SMI disorders may also present with distinct mortality associations. We therefore con-
sidered schizophrenia, schizoaffective disorders, and bipolar disorders as separate entities for
the present study, though we acknowledge the substantial overlap in the probable drivers of
excess mortality.[25]
Modifiable risk factors. The present study focused on natural causes of death and was
restricted to risk factors known to be amenable and preventable within the SMI population. In
the context of the present study, a modifiable risk factor was defined as an event known to
directly or indirectly increase the probability of death and for which there are proven methods
to reduce the impact on all-cause mortality in people with SMI.[26] These factors include
behavioural risk factors (e.g. smoking, physical inactivity, obesity, poor diet, substance abuse)
and healthcare-related factors (e.g. uptake of public health interventions, uptake of effective
treatment, access to healthcare resources), as well as upstream socioeconomic determinants
(e.g. social exclusion, stigma, deprivation). A multicontextual view of avoidable mortality was
favoured since it spans the different levels of explanation for the reduced life expectancy within
the SMI population as defined here. It also facilitates the identification of proven interventions
to reduce the mortality gap between people with and without SMI.[27]
Statistical analysis
Prevalence of modifiable risk factors, relative risk for all-cause mortality, and the effectiveness
of existing interventions were identified through systematic searches of published data. To
determine the proportion of mortality burden attributable to each modifiable risk factor we
computed the population-attributable fraction (PAF) from the prevalence (Pcs) of modifiable
risk factors and unadjusted relative risk (RRcs) of all-cause mortality associated with each risk
factor separately, using the formula:
PAF ¼ PcsðRRcs   1Þ=PcsðRRcs   1Þ þ 1 ð1Þ
The PAFs for all-cause mortality associated with a modifiable risk factor were computed
using the prevalence and RR estimates obtained from meta-analysis or individual studies. The
PAF is interpreted as the proportion of mortality risk that could be eliminated from the SMI
population, if the exposure to the risk factor was eliminated or reduced. To allow for the over-
lap between different modifiable risk factors in influencing all-cause mortality, we have also
estimated the combined impact of multiple modifiable risk factors within each group of
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determinants (e.g. behavioural, healthcare, social) and across all modifiable risk factors using,
[28]
PAFcombined ¼ 1  pð1  PAFrÞ ð2Þ
where r is the risk factor index. While the formula assumes no interaction effects, it ensures
that the PAF for the combined contribution of modifiable risk factors to all-cause mortality is
not greater than 1.[28]
To estimate likely gain in life expectancy from specific interventions in SMI, we adjusted
the PAF value of modifiable risk factors by the effectiveness of interventions aimed at reducing
the rate of modifiable risk factors within the SMI population. For example, if the PAF for
smoking was 46% (based on (1) above), then this figure was weighted by the effectiveness of
smoking cessation interventions in people with SMI. If the effectiveness of smoking cessation
among people with SMI would be around 36%,[29] then the likely gain in life expectancy at
birth with respect to smoking would be based on the assumption that 17% (0.46 weighted by
0.36) of smoking-related mortality risk could be potentially eliminated from people with
schizophrenia. Data on the effectiveness of interventions were only available at aggregate level.
Abridged period life table, based on the Chiang’s method,[30] for 2014–2015 were used to
describe the base case population for life expectancy and all-cause mortality rates in United
Kingdom (UK) adults with SMI. The 2014–2105 period represents the most recent data (2018)
released by the National Health Service Outcome Framework Indicators (NHS QoF),[31]
which includes aggregated mortality rate and population data into 5-year age intervals for SMI
adults 18 to 74 years of age. For SMI adults aged 75 years or older, the mortality rates were cal-
culated based on 2014–2015 mortality data among adults of similar age from the general popu-
lation. Specifically, we have multiplied the mortality rate for 2014–2015 among adults aged 75
years or over from the general population by the increased mortality risk among adults aged
75 years or over with SMI (e.g. 2.5 for 75–79, 1.9 for 80 to 84, and 1.3 for 85+ year-group)
using published data.[32] For instance, the mortality rate in 2014–2105 for SMI adults aged 75
to 79 years was estimated to be 2.5 times greater (0.0835) than the 0.0334 mortality rate experi-
enced by 75–79 years old adults from the general population during 2014–2015. Because youn-
ger people (<15 years of age) are unlikely to receive a diagnosis of SMI,[1] we have used the
UK all-cause mortality rates for the under 18 year age group in substitution. Separate abridged
life tables were constructed for each modifiable risk factor. These mortality rates were used to
create a cause-eliminating life table to estimate the potential gain in life expectancy at birth if
modifiable risk factors could be reduced or eliminated within specific SMI subgroups.[33] The
gain in life expectancy represents the change in life expectancy at birth that would be obtained
under the hypothetical reduction of the cause (modifiable risk factors) of premature mortality
within specific SMIs subgroups. Let 65.9 years denote the life expectancy at birth (age 0) from
actual life table for a person with schizophrenia, and 68.3 year denote life expectancy at birth
from smoking(cause)-eliminated life table for the same person. Then the gain in life expec-
tancy at birth due to smoking(cause) elimination or reduction is 2.4 years (68.3–65.9). This
approach has been widely employed to estimate the potential gain in life expectancy if a spe-
cific cause could be reduced or eliminated.[34] To capture potential gain in life expectancy
across the life course and to allow for the fact that people are diagnosed with SMI at different
life stages,[35] we have estimated two additional scenarios: (I) potential gain in life expectancy
among people with SMI who survive to age 50, and (II) potential gain in life expectancy
among people with SMI who survive to age 65. For (I), the analyses estimated the average
remaining years of life that SMI survivors to age 50 were expected to live if mortality levels at
PLOS ONE Life expectancy gains in severe mental illness
PLOS ONE | https://doi.org/10.1371/journal.pone.0230674 March 27, 2020 4 / 16
each age-group over 50 remained constant.[36] A similar approach was used for age 65 (II).
[37]
To quantify the expected average annual amount of change in life expectancy, we have
divided the total gain in life expectancy at birth by the number of years during a specific
period. Given the stable mortality rates and modest change in life expectancy over the past
decade within the general population,[38] we have considered a 20-year period as a reasonable
timeframe for projecting likely average annual amount of change in life expectancy among
people with SMI. In addition, we computed the arithmetic average percentage of change in life
expectancy during a 20-year period by dividing the average amount of annual change by the
expectancy value at the beginning of the period, using the following formula: [33]
1. Lex2030/Lex2018 = e
rt(20) (3)
2. transform (1) in ln: ln(Lex2038 / Lex2018) = rt
3. dividing (2) by (1): ln(Lex2038 / Lex2018)/t = r
Where, Lex2038, represent life expectancy in 2038, and Lex2018 refers to life expectancy in
2018., r represents the Annual Percentage Change (APC), and t the number of years. In sensi-
tivity analyses, we applied average all-cause mortality rates over a five-year period (2009/2010
to 2014/2015) using mid-interval (2011/2012) population as the denominator to assess the
robustness of our findings. We used Stata vers. 15 and Excel to analyse the data.
Results
Table 1 shows the estimates for the prevalence of modifiable risk factors within specific SMI
subgroups. According to most recent meta-analyses,[39, 40] around 59% of people with
schizophrenia and 49% of those with bipolar disorder are current smokers. Accelerometry-
based evidence indicated that sedentary behaviour was common among 81% of people with
schizophrenia and 78% among those with bipolar disorders[41, 42]. The uptake of public
health interventions (i.e. screening, preventative initiatives) was also poor, with around 50% of
people with SMI not being screened for CVD risk factors.[39] Low rates of receiving specialist
treatment following a major life event were identified, with 47% of the SMI population not
receiving revascularisation procedures following a myocardial infarction, for instance.[43]
Regarding social context, around 65% and 55% of people with schizophrenia or bipolar disor-
ders, respectively, reported the experience of stigma.[44, 45]
Lifestyle risk factors
Table 2 shows potential gains in life expectancy at birth, and ages 50 and 65 years associated
with tackling modifiable risk factors for all-cause mortality in specific SMIs. Smoking-related
conditions accounted for 46% of all deaths in schizophrenia and 22% of all deaths in bipolar
disorders (based on formula (1) above). Based on age-aggregated effectiveness of existing
smoking-cessation interventions, smoking-targeted initiatives have the potential to extend the
life expectancy at birth by on average two years and five months within schizophrenia or schi-
zoaffective disorders, and by one year and one month within bipolar disorders. Potential gain
in life expectancy at age 50 related to smoking-targeted interventions, was two years within
schizophrenia or schizoaffective disorders, and nine months among bipolar disorder. Likewise,
potential gain in life expectancy at age 65 from smoking-targeted interventions was one year
and seven months within schizophrenia or schizoaffective disorders, and seven months among
bipolar disorder. Sedentary behaviour was the most potent determinant of avoidable mortality
within bipolar disorders, accounting for just over a third (34%) all-cause mortality (using
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formula (1) above). Physical inactivity-focused interventions could extend life expectancy at
birth among the SMI subgroups by on average one year and three months. Under an additive
scenario, tackling behavioural and metabolic determinants of avoidable mortality would lead
to a potential gain in life expectancy at birth of four (bipolar disorders) or six (schizophrenia)
years. The combined gain in life expectancy at age 50 years was three (bipolar disorders) or
five (schizophrenia) years, while at age 65 years it was two (bipolar disorders) or four (schizo-
phrenia) years.
Healthcare systems determinants
Table 2 illustrates that ineffective access to healthcare resources accounted for a larger propor-
tion of all-cause mortality within schizophrenia and schizoaffective disorders (14%) relative to
bipolar disorders (5%). Allowing for the effectiveness of current interventions, the potential
gain in life expectancy at birth by tackling inadequate healthcare access was three (bipolar dis-
orders) or seven (schizophrenia and schizoaffective disorders) months. The figures in Table 2
have been weighted to reflect the fact that only 30% of people with schizophrenia (treatment-
resistant patients) are currently prescribed clozapine. Consequently, improved clozapine pre-
scribing among eligible patients with schizophrenia and improved lithium prescribing within
bipolar disorder patients could lead to potential gains in life expectancy at birth of around
three months or one year, respectively. Additional gain in life expectancy at age 50 associated
with clozapine was two months (schizophrenia) and eight months for lithium (bipolar disor-
ders). Under an additive scenario, improving healthcare practices and processes could increase
life expectancy at birth by seven or eight months within the SMI population.
Social determinants
Within social determinants, social deprivation accounted for the largest proportion of avoid-
able mortality within schizophrenia (21%), schizoaffective disorders (19%), and bipolar
Table 1. Prevalence of modifiable risk factors within specific SMIs and the general population.
Schizophrenia Bipolar disorder Schizoaffective disorders
% RR % RR % RR
LIFESTYLE FACTORS
Smoking 59 2.45 49 1.57 59 2.50
Sedentary 81 1.66 78 1.66 81 1.66
Diet 69 1.53 69 1.53 69 1.53
Obesity 50 1.47 50 1.47 50 1.47
Substance abuse 47 1.78 45 1.89 54 1.78
Metabolic syndrome 33 2.10 32 1.70 35 2.10
HEALTHCARE FACTORS
Clozapine/Lithium 24 1.88 29 1.70 24 1.88
Healthcare access 46 1.34 46 1.11 46 1.34
Treatment disparity (e.g. revascularisation) 47 1.15 47 1.15 47 1.15
Screening uptake 50 1.18 50 1.18 50 1.18
SOCIAL FACTORS
Social deprivation 30 1.90 26 1.30 26 1.90
Social isolation 32 1.19 21 1.19 32 1.19
Stigma experience 65 1.12 55 1.12 49 1.12
RR–relative risk of mortality given the risk factor
https://doi.org/10.1371/journal.pone.0230674.t001
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disorders (7%). Tackling social deprivation-related inequalities within the SMI population has
the potential to increase the life expectancy at birth by on average three (bipolar disorders),
five (schizoaffective disorders), or seven (schizophrenia) months. Under an additive scenario,
tackling social determinants of all-cause mortality within SMI may increase life expectancy at
birth on average by one (bipolar disorders), two (schizoaffective disorders), or four (schizo-
phrenia) months. The potential gain in life expectancy at ages 50 and 65 years from tackling
social deprivation was one (bipolar) to three (schizophrenia) months.
When estimated collectively, behavioural habits, healthcare practices, and social determi-
nants accounted for 90% (bipolar disorders) and 95% (schizophrenia and schizoaffective disor-
ders) of all-cause mortality. Allowing for the effectiveness of existing interventions, tackling
these modifiable risk factors would lead to a potential gain in life expectancy at birth of four
years within bipolar disorders, six years within schizoaffective disorders, or seven years within
schizophrenia. Assuming similar APC in life expectancy within men and women with schizo-
phrenia, the estimated life expectancy gain would gradually narrow the current life expectancy
gap on average by three years for men and four years among women during a 20-year period
(Fig 1). Sensitivity analyses using the average five-year mortality rate produced only marginally
Table 2. Potential gains in life expectancy at birth and ages 50 and 65 years associated with modifiable risk factors for all-cause mortality in specific SMIs.
Schizophrenia Bipolar disorders Schizoaffective disorders
ES (%) PAF (%) LYG–age Birth 50 65 PAF (%) LYG- age Birth 50 65 PAF (%) LYG- age Birth 50 65
LIFESTYLE MODEL
Smoking 36 46 2.5 2.1 1.7 22 1.1 0.9 0.7 46 2.5 2.1 1.7
Sedentary 25 35 1.3 1.0 0.8 34 1.3 1.0 0.8 35 1.3 1.0 0.8
Diet 31 27 1.1 0.9 0.7 27 1.1 0.9 0.7 27 1.1 0.9 0.7
Obesity 24 19 0.7 0.6 0.5 19 0.7 0.6 0.5 19 0.7 0.6 0.5
Substance abuse 17 27 0.7 0.6 0.5 29 0.7 0.6 0.5 30 0.7 0.6 0.5
COMBINEDb 85 5.4 4.4 3.6 78 3.8 3.1 2.5 85 5.4 4.4 3.6
Metabolic syndrome 30 27 1.1 0.9 0.7 18 0.8 0.6 0.4 28 1.1 0.9 0.7
COMBINED (lifestyle) 89 5.8 4.7 3.8 82 3.8 3.0 2.4 89 5.8 4.7 3.8
HEALTHCARE MODEL
Clozapine/Lithiumb 13/38 17 0.3 0.2 0.2 17 0.9 0.7 0.6 17 0.3 0.2 0.2
Healthcare access 38 14 0.7 0.6 0.5 5 0.3 0.2 0.2 14 0.7 0.6 0.5
Treatment disparity 37 7 0.4 0.3 0.3 7 0.4 0.3 0.3 7 0.4 0.3 0.3
Screening uptake 41 8 0.4 0.3 0.3 8 0.4 0.3 0.3 8 0.4 0.3 0.3
COMBINED 37 0.7 0.5 0.5 36 0.8 0.6 0�5 37 0.7 0.5 0.5
SOCIAL MODEL
Social deprivation 23 21 0.7 0.6 0.5 7 0.3 0.2 0.2 19 0.5 0.4 0.4
Social exclusion 38 6 0.3 0.2 0.2 4 0.3 0.2 0.2 6 0.3 0.2 0.2
Stigma experience 24 7 0.3 0.2 0.2 6 0.1 0.1 0.1 6 0.1 0.1 0.1
COMBINED 30 0.4 0.3 0.3 16 0.1 0.1 0.1 28 0.2 0.2 0.2
ATTAINABLEc 95 6.6 5.2 4.4 90 4.2 3.3 2.7 95 6.4 5.1 4.3
APCd 5% 0.3 0.3 0.2 5% 0.2 0.2 0.1 5% 0.3 0.3 0.2
ES- effectiveness of existing interventions at reducing the rate of risk factors. PAF–population attributable fraction; LYG–life years gained at specific ages from reducing
a cause weighted by the ES
a Combined = comorbidity adjusted gain in life expectancy for specific determinants
b Lithium is prescribed for bipolar disorder, mainly. Clozapine has been adjusted to reflect that only a third of patients are eligible for prescribing
c Attainable = potential gain in life expectancy considering the combined effect of multiple risk factors
d APC–annual percentage change, together with amount of annual change (rounded data) in life expectancy.
https://doi.org/10.1371/journal.pone.0230674.t002
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lower estimates for gain in life expectancy across the life course validating the robustness of
our findings (S2 Table in S1 File).
Discussion
The present study employed a multicontextual approach to quantify potential gains in life
expectancy from tackling modifiable causes of premature mortality within specific SMI sub-
groups. The present study modeling approach relied on two assumptions that (a) the estimated
average effectiveness of interventions represented all studies and countries, and (b) that mor-
tality rates of UK adults with SMI applied universally. Accounting for the combined effects of
multiple modifiable risk factors, our findings indicated that an attainable target for gain in life
expectancy at birth among people with SMI would be around six and a half years for schizo-
phrenia and schizoaffective disorders, and around four years within bipolar disorders. When
projected during a 20-year period, these estimates translated into an average annual percentage
change in life expectancy at birth of between two to three months (5%). Assuming similar gain
in life expectancy at birth among men and women with SMI and using national forecasts for
the UK general population, we projected 24% (men) to 28% (women) narrowing of the mortal-
ity gap between the general and the SMI populations over a 20-year target. We also estimated
that tackling modifiable risk factors for natural causes of death could extend life expectancy at
age 50 years three (bipolar disorders) or five (schizophrenia or schizoaffective disorders) years.
In addition, tackling modifiable risk factors could extend life expectancy at age 65 years by
three (bipolar disorders) or four (schizophrenia and schizoaffective disorders) years.
Fig 1. Trends in life expectancy gain at birth and projected gap (LE Gap) between the general population (GP) and the schizophrenia (SMI) population over a
two-decade period.
https://doi.org/10.1371/journal.pone.0230674.g001
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The implementation of lifestyle interventions depends also on achieving increased accep-
tance and participation rates on the part of patients. SMIs are commonly associated with
impairment in patients’ awareness about the implications of unhealthy behaviours or treat-
ment non-adherence to their health and wellbeing. Poor insight into the illness and its treat-
ment, may challenge clinicians’ capacity to convince SMI patients to adopt healthy behaviours
or adhere to treatment. These suggestions are supported by recent evidence documenting that
people with SMI failed to manifest similar reduction in mortality rates due to natural causes
observed in the general populations over the past decades.[46] Future studies are needed to
identify how best to enhance SMI patients’ awareness about the benefits of treatment compli-
ance and lifestyle changes to their health and quality of life.
Smoking emerged as the best single modifiable candidate for increasing life expectancy
within schizophrenia (2.4 years), while sedentary behaviour (1.2 years) appeared to be the best
single modifiable candidate for increasing life expectancy within bipolar disorder. Yet, lifestyle
behaviours within the SMI population continue to be marginalised and poorly integrated into
care pathways.[47] For instance, health care professionals were often reluctant to engage in
smoking cessation behaviours[48] and smoking cessation services may be less accessible to
people with SMI.[49] On the positive side, however, people with SMI appeared equally moti-
vated to want to change negative lifestyle behaviours [50]–though interventions may be less
effective.[51] A recent trial illustrated, for instance, that a bespoke smoking cessation interven-
tion embedded in routine mental health care settings[52] was associated with a 56% greater
reduction in smoking rates compared to usual care within people with schizophrenia and
bipolar disorder. Other studies suggested, however, lower rates of smoking cessation.[53]
Regardless of these variation, such findings lend support to our proposed gain in life expec-
tancy within the SMI population, if the effectiveness of current lifestyle interventions can be
maintained or improved in the long-term.
Despite valid concerns[54–58] about a potential association between antipsychotic drugs
with increased risk of metabolic disorders, previous studies revealed a potential for clozapine
and lithium to reduce premature mortality among people with schizophrenia and bipolar dis-
orders.[59–61] This may seem counter-intuitive given that clozapine is prone to cause obesity,
diabetes, cardiomyopathy[58] and, rarely, agranulocytosis, as well as being reserved for the
most severe, treatment resistant group. Also, lithium has a narrow therapeutic range, and is
potentially associated with renal impairment or failure.[62,63] Prior research suggest that
some of these side-effects may be offset by the evidence for reduced all-cause mortality. For
instance, studies have shown up to 50% reduction in all-cause mortality among people with
schizophrenia receiving clozapine compared to those never prescribed the drug.[64] The
mechanisms through which these drugs have their beneficial effects may be a direct conse-
quence of treatment on mental health symptoms, or on service related factors such as contin-
ued monitoring and continuity of care which is necessitated by the routine monitoring
involved. While effective, clozapine and lithium are not always accepted by patients and
require expertise and experience in order to be prescribed safely. Thus, there are implementa-
tion challenges to any policy highlighting their wider use.
The findings also underline the potential for additional gain in life expectancy through
facilitating timely access to healthcare resources and improved prescribing practices. Poor
access to healthcare resources contribute to increased mortality rates among people with SMI,
[65] though UK estimates of reduced life expectancy in people with SMI are less dramatic than
those arising from other healthcare systems[66] (possibly reflecting the universal access offered
by the NHS). A confluence of clinician (e.g. insufficient assessment, poor communication,
suboptimal prescribing habits), service providers (e.g. poor care coordination, insufficient
funds), and patient (e.g. low motivation leading to poor adherence to treatment, difficulties in
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understanding health care advice) factors may account for the poor access to and quality of
health care among people with SMI. These factors all contribute to the reduced life expectancy
among people with SMI, [67] as documented in this study. Recent research has confirmed dis-
parities in access to specialist medical interventions (e.g. revascularisation) following a major
health event among people with SMI.[68] Diagnostic delays related to physical comorbidities
[69, 70] may also interfere with timely access to healthcare resources and effective treatment,
increasing the risk of premature mortality. Our study findings suggest that tackling patient
and health system barriers to accessing relevant healthcare resources and medical interven-
tions would extend life expectancy by four to eight months across the life course within the
broader SMI population.
Stigma and social isolation may influence mortality outcomes indirectly by impacting on
lifestyle behaviours, treatment continuation or adherence, and the timely utilisation of health-
care resources.[71]. Stigma associated with SMI has been identified as a major barrier to
accessing treatment and health care resources, and it occurs at all levels including healthcare
professionals, society, and individuals.[72]. Similarly, socioeconomic inequalities in mortality
outcomes among people with SMI are likely to reflect inequalities in access to healthcare
resources, low health care-seeking behaviour, poorer knowledge of physical health symptoms
and risk factors, and motivational challenges to accessing healthcare support. Our findings
implied that the implementation of wider initiatives to tackle poverty and stigma would
improve life expectancy among people with SMI by around 10%.
Strengths and limitations of this study
To our knowledge this is the first study to consider both the population attribution fraction
and the effectiveness of interventions in calculating the expected gain in life expectancy over
the life course within specific SMI populations. Another major strength is the use of a multi-
contextual approach to estimates potential gain in life expectancy over the lifecourse across
specific SMI subgroups. Our estimation model shares limitations common to most projections
of future gain in life expectancy, such as proportionality hypothesis (e.g. constant mortality
rates and intervention effectiveness over time). We have partially addressed this concern by
adopting short-term projections and conducting sensitivity analyses averaging mortality rates
over a five-year period. Also, our estimates for treatment impact on life expectancy gains have
been constrained to two drugs with the greatest evidence on harms and benefits within the
SMI populations. Thus, our findings may not generalise to patients prescribed other antipsy-
chotic or antidepressant drugs, or to polypharmacy. Given limited resources, it is not always
possible to conduct studies on all issues in all settings prior to making a policy decision. This
was also the case with the present study, where no single country collected relevant data on all
study parameters estimated in the models. This concern places constraints about the generaliz-
ability of present study findings across different countries with varying healthcare and socio-
economic contexts. Ultimately, it is the responsibility of decision-makers to consider the
extent to which evidence from one setting (UK) is transferrable to a different setting. Regard-
less, the framework set out in this study identified critical gaps in the current evidence base
that may encourage future research and developments into modeling gains in life expectancy
from addressing modifiable determinants of premature mortality among people with SMI.
There were suggestions that PAF formula may overestimate excess burden of all-cause mortal-
ity due to smoking, [73] and this concern applies to our study estimates including the high col-
lective estimates. Further, when confounders exist and one does not correct for this, the PAF is
likely to be influenced. Moreover, residual confounding also exists and therefore the PAF suf-
fers from overestimation. PAF estimates tend to vary, however, across populations, over time
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and with different ranking of common mortality causes.[74] It also provides healthcare pro-
viders and policy makers with a useful tool to interpret the excess mortality due to specific fac-
tors among people with SMI.[74] The healthcare is a more complex system than
conceptualised here, and our findings may underestimate the potential gain in life expectancy
from healthcare-based interventions within the broader SMI population. Interventions at any
level of the healthcare system, however, will be reflected in changes across other parts of the
system including the healthcare characteristics considered in this study. Moreover, while the
gap in life expectancy among men and women with SMI is similar (i.e. 13 and 12, respectively,
years) future studies assessing possible differential gain in life expectancy among men and
women with specific SMIs are warranted. When translating evidence from well-controlled tri-
als into clinical practice, the dilution of the intervention effect is common. This concern is
exacerbated by SMI patients representing a challenging group to treat, for several reasons (e.g.
reduced insights into their condition, concerns around drugs side-effects). These concerns
imply the need for greater efforts to accomplish the effects sizes used in our modeling
approach. Several suggestions were put forward (e.g. improved mental and study physical care
coordination, address patients’ resistance to treatment or screening uptake) how this could be
achieved, yet, evidence to confirm the feasibility of these proposals is currently lacking. Finally,
our study estimates relied on UK-based data for mortality rates, while data on prevalence of
modifiable risk factors and effectiveness of interventions coming mainly from developed coun-
tries. These estimates may not be directly transferrable to other countries with a different care
system and epidemiology of risk factors social circumstances, or health care provision. We
have aimed to moderate this concern by relying, whenever possible, on meta-analysis findings
that accounts for variation in different study designs and methodology.
Conclusion
Our study findings indicated that addressing unhealthy behaviours, suboptimal use of health-
care resources, and poor life circumstances have the potential prolong life expectancy at birth
by four and six years within bipolar or schizophrenia disorders. If our study estimates are
translatable into routine practice, we would expect around 24% (men) to 28% (women) nar-
rowing in the life expectancy gap between the SMI and the general population from tackling
modifiable risk factors. Given similar or greater life expectancy gaps in other Western coun-
tries these results suggest that at least comparable improvements in the longevity of people
with SMI can be achieved elsewhere. Achieving these projections requires multisectoral
approach to ensure that the complexity of SMI disorders are addressed at individual, clinical,
and societal level.[75] The study findings need to be interpreted cautiously since translation of
clinical trials evidence into routine care it is often challenging and ineffective.
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